Abstract: An injector includes a push rod, a magazine tube, a gate, a cannula and an actuator. The magazine tube has a lumen extending from an inlet to an outlet thereof. The magazine tube slidingly receives at least one implant therein. The gate has a closed configuration in which it covers the outlet of the magazine tube and an open configuration in which it does not cover the outlet of the magazine tube. The cannula has a distal end configured to be inserted into an eye. A lumen of the cannula is in fluid communication with the lumen of the magazine tube when the gate is in the open configuration. Actuation of the actuator moves the gate from the closed configuration to the open configuration and causes translation of the pushrod through the magazine tube and the cannula.

Abstract: The present invention is related to a combination for obtaining improved stability of a Vitamin A ester and Vitamin C formulation, achieved via including a specific Vitamin A derivative and one of several other Vitamin C derivatives. This combination shows an enhanced stability in varied cosmetic formulations as a function of time and at different environmental conditions.

Abstract: This disclosure features compositions (e.g., re-constitutable solids, such as lyophilized cakes; or liquid compositions, such as solutions or suspensions, e.g., reconstituted lyophilized cakes) that are suitable for subcutaneous administration. The compositions include a crystalline form (e.g., Form A) of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol, free base and one or more pharmaceutically acceptable excipients and/or one or more pharmaceutically acceptable carriers (e.g., one or more bulking agents; one or more dispersing agents; one or more buffers; one or more suspending agents; water, e.g., water for injection (“WFI”)).

Abstract: We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.

Abstract: We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.

Abstract: We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.

Abstract: We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.

Abstract: Robust sustained release formulations, solid dosage forms comprising robust sustained release formulations, and methods for making and using these formulations and solid dosage forms are provided. Robustness of the sustained release formulation is related to the particle size of the hydrophilic gum. Sustained release formulations resist dose-dumping when ingested with alcohol. The formulations are useful for treating a patient suffering from a condition, e.g., pain. The formulations comprise at least one drug. In one embodiment, the drug is an opioid, e.g., oxymorphone.

Abstract: Robust sustained release formulations, solid dosage forms comprising robust sustained release formulations, and methods for making and using these formulations and solid dosage forms are provided. Robustness of the sustained release formulation is related to the particle size of the hydrophilic gum. Sustained release formulations resist dose-dumping when ingested with alcohol. The formulations are useful for treating a patient suffering from a condition, e.g., pain. The formulations comprise at least one drug. In one embodiment, the drug is an opioid, e.g., oxymorphone.

Abstract: A symmetric objects database contains a plurality of data cells. Each data cell has a plurality of data fields which are the same or similar for each of the data cells. The data fields include an identifier field, name field, value field, signature field, classes field, children field, versions field, user ID field, date field, and control flag field. A first data cell is related or linked to a second data cell which is higher in database hierarchy than the first data cell. The linking is done through the classes field within the first data cell which contains the identifier of the second data cell. A third data cell is related or linked to a fourth data cell which is lower in database hierarchy than the second data cell. The linking is accomplished through the children field which contains the identifier of the fourth data cell. A versions field keeps track of historical changes to the database. The later version of a data cell links to the identifier of an earlier version of the data cell.

Abstract: A symmetric objects database contains a plurality of data cells. Each data cell has a plurality of data fields which are the same or similar for each of the data cells. The data fields include an identifier field, name field, value field, signature field, classes field, children field, versions field, user ID field, date field, and control flag field. A first data cell is related or linked to a second data cell which is higher in database hierarchy than the first data cell. The linking is done through the classes field within the first data cell which contains the identifier of the second data cell. A third data cell is related or linked to a fourth data cell which is lower in database hierarchy than the second data cell. The linking is accomplished through the children field which contains the identifier of the fourth data cell. A versions field keeps track of historical changes to the database. The later version of a data cell links to the identifier of an earlier version of the data cell.

Abstract: The present invention pertains to a pharmaceutical dosage form comprising an opioid agonist and one or more opioid antagonists contained in a matrix separate from the opioid agonist. The separate matrix for the opioid antagonist allows independent release rates to be achieved for the opioid and opioid antagonist(s). The antagonist(s) can be released slowly or fully contained when the tablet is taken orally. Crushing the tablet allows full release of the antagonist(s), deterring abuse. The abuse deterring antagonist(s) may be an opioid antagonist, an irritant, another appropriate antagonist(s), or a combination thereof. The invention also allows variable release of the opioid and antagonist(s).

Abstract: An antigel agent composed of four types of antioxidants that allows polyamides to be blended with acrylonitrile/butadiene polymers with minimum generation of gels and yields a blend which can be extruded or sheeted to give a uniformed shaped product, for example, sheets and molded articles and is essentially free of plugging the screens of extruder used to extrude hose tube or sheet.